These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9833163)

  • 1. Clinical efficacy of a new AT1 blocker.
    Philipp T; Heemann U
    Basic Res Cardiol; 1998; 93 Suppl 2():51-3. PubMed ID: 9833163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving antihypertensive efficacy while maintaining placebo-like tolerability.
    Sever PS
    Blood Press Suppl; 2000; 1():19-22. PubMed ID: 11059631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candesartan cilexetil: an angiotensin II-receptor blocker.
    See S; Stirling AL
    Am J Health Syst Pharm; 2000 Apr; 57(8):739-46. PubMed ID: 10786259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Angiotensin receptor antagonist for therapy of patients with hypertension].
    Rakugi H; Ogihara T
    Nihon Rinsho; 1997 Aug; 55(8):2075-80. PubMed ID: 9284426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achieving quality 24-h blood pressure control with candesartan cilexetil.
    Meredith P
    Blood Press Suppl; 2000; 1():23-6. PubMed ID: 11059632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
    Sever P
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S91-5. PubMed ID: 9331018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators.
    Reif M; White WB; Fagan TC; Oparil S; Flanagan TL; Edwards DT; Cushing DJ; Michelson EL
    Am J Cardiol; 1998 Oct; 82(8):961-5. PubMed ID: 9794352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy-safety relationship of AT1 angiotensin II receptor antagonists: current data].
    Paoletti V; Di Veroli C; Pugliese M; Cammarella I; Cavina G; Turchetti P; Mammarella A
    Clin Ter; 2002; 153(1):61-4. PubMed ID: 11963637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA; McVoy HJ; Kaul AF
    Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.
    Malmqvist K; Kahan T; Dahl M
    Am J Hypertens; 2000 May; 13(5 Pt 1):504-11. PubMed ID: 10826401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different?
    Unger T
    Am J Cardiol; 1999 Nov; 84(10A):9S-15S. PubMed ID: 10588089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.
    Bönner G; Fuchs W
    Curr Med Res Opin; 2005 Jun; 21(6):935-40. PubMed ID: 15969893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability of a modern antihypertensive agent: candesartan cilexetil.
    Andersson OK
    Basic Res Cardiol; 1998; 93 Suppl 2():54-8. PubMed ID: 9833164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newly emerging pharmacologic differences in angiotensin II receptor blockers.
    Oparil S
    Am J Hypertens; 2000 Jan; 13(1 Pt 2):18S-24S. PubMed ID: 10678284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preserving target-organ function with candesartan cilexetil in patients with hypertension.
    Zannad F
    Blood Press Suppl; 2000; 1():36-9. PubMed ID: 11059635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving prognosis in hypertension: exploring the benefits of angiotensin II type 1 receptor blockade.
    Ruilope L
    Blood Press Suppl; 2000; 1():31-5. PubMed ID: 11059634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators.
    Kloner RA; Weinberger M; Pool JL; Chrysant SG; Prasad R; Harris SM; Zyczynski TM; Leidy NK; Michelson EL;
    Am J Cardiol; 2001 Mar; 87(6):727-31. PubMed ID: 11249891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Irbesartan--a new AT1-receptor antagonist (AT1-blocker). Angiotensin-II-receptor antagonists: perspectives of a new therapeutic principle, Wiesbaden, 6 April 1997].
    Dtsch Med Wochenschr; 1997 Sep; 122(37 Suppl):1-4. PubMed ID: 9330579
    [No Abstract]   [Full Text] [Related]  

  • 19. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators.
    Lacourcière Y; Asmar R
    Am J Hypertens; 1999 Dec; 12(12 Pt 1-2):1181-7. PubMed ID: 10619580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators.
    Oparil S; Levine JH; Zuschke CA; Gradman AH; Ripley E; Jones DW; Hardison JD; Cushing DJ; Prasad R; Michelson EL
    Am J Cardiol; 1999 Aug; 84(3):289-93. PubMed ID: 10496437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.